| Q33929574 | A risk-benefit assessment of drugs used for neonatal chronic lung disease |
| Q43934230 | Bronchopulmonary dysplasia and corticosteroid therapy |
| Q40683529 | Cardiac adverse effects of early dexamethasone treatment in preterm infants: a randomized clinical trial |
| Q52545402 | Cecal colonization and systemic spread of Candida albicans in mice treated with antibiotics and dexamethasone. |
| Q78106575 | Chronic lung disease of prematurity--prevention by inhaled corticosteroids? |
| Q33996589 | Clinical implications of inflammation in young children |
| Q28551761 | Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation |
| Q35040305 | Cognitive and behavioral deficits in premature graduates of intensive care |
| Q34353377 | Cumulative perinatal steroids: child development of preterm infants |
| Q33999251 | Current perspectives on the drug treatment of neonatal respiratory distress syndrome |
| Q33631717 | Decreasing incidence of chronic lung disease despite the gradual reduction of postnatal dexamethasone use in very low birth weight infants |
| Q24250246 | Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants |
| Q24194710 | Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants |
| Q24240398 | Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants |
| Q24241263 | Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants |
| Q47235844 | Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. |
| Q24197860 | Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates |
| Q24243622 | Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates |
| Q30867509 | Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. |
| Q30239811 | Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. |
| Q24250213 | Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants |
| Q47139802 | Efficacy of glucocorticoids, vitamin A and caffeine therapies for neonatal mortality in preterm infants: a network meta-analysis |
| Q35291674 | Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease |
| Q77318029 | Gains and losses from dexamethasone for neonatal chronic lung disease |
| Q32027082 | Growth restriction in dexamethasone-treated preterm infants may be mediated by reduced IGF-I and IGFBP-3 plasma concentrations |
| Q48829464 | Hedgehog rushes to the rescue of the developing cerebellum |
| Q28188786 | Human SP-A 3'-UTR variants mediate differential gene expression in basal levels and in response to dexamethasone |
| Q37106309 | Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia. |
| Q34074045 | Inhaled glucocorticoid therapy in infants at risk for neonatal chronic lung disease |
| Q47181565 | Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. |
| Q24197850 | Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates |
| Q24250182 | Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates |
| Q47182016 | Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. |
| Q24197845 | Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants |
| Q45158552 | Injectable dexamethasone administration enhances cortical GABAergic neuronal differentiation in a novel model of postnatal steroid therapy in mice |
| Q24194676 | Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants |
| Q47235829 | Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. |
| Q24241502 | Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants |
| Q93486947 | L’administration postnatale de corticoïdes pour traiter ou prévenir les affections pulmonaires chroniques chez les prématurés |
| Q35552698 | Mimicking maternal smoking and pharmacotherapy of preterm labor: fetal nicotine exposure enhances the effect of late gestational dexamethasone treatment on noradrenergic circuits |
| Q24250284 | Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants |
| Q33183147 | Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives |
| Q35294254 | Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids |
| Q40426779 | Pediatric Respiratory Assembly. Mini symposium on lung inflammation |
| Q24187852 | Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants |
| Q24201869 | Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants |
| Q74168011 | Perinatal administration of dexamethasone. What benefits in the premature infant |
| Q59632099 | Post-natal corticosteroid use |
| Q46217179 | Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study |
| Q33888778 | Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function |
| Q82384735 | Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants |
| Q34074665 | Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease |
| Q30907696 | Postnatal steroid treatment and brain development |
| Q44326829 | Prediction of outcome from the chest radiograph appearance on day 7 of very prematurely born infants |
| Q35289859 | Randomised trial of fluid restriction in ventilated very low birthweight infants |
| Q73728754 | Statement on the care of the child with chronic lung disease of infancy and childhood |
| Q43160711 | Stopping the swinging pendulum of postnatal corticosteroid use. |
| Q33954018 | Weaning from assisted ventilation: art or science? |
| Q81522942 | [Postnatal steroid treatment in preterm infants: risk/benefit ratio] |
| Q79335630 | [Ventilation in special situations. Neonatal mechanical ventilation] |